PubRank

George Coukos

Author PubWeight™ 244.67‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 22.96
2 Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003 16.62
3 Cancer immunotherapy comes of age. Nature 2011 12.35
4 microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006 8.24
5 The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008 7.86
6 Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011 5.28
7 Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009 4.80
8 Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A 2008 4.79
9 Modulation of the antitumor immune response by complement. Nat Immunol 2008 4.53
10 Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011 4.07
11 miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2007 3.93
12 Laser-capture microdissection. Nat Protoc 2006 3.80
13 Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004 3.55
14 Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. PLoS One 2010 3.38
15 Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008 3.35
16 Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013 3.27
17 Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol 2011 2.67
18 T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012 2.43
19 MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res 2008 2.35
20 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
21 Mechanisms of microRNA deregulation in human cancer. Cell Cycle 2008 2.30
22 Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 2007 2.25
23 Deciphering and reversing tumor immune suppression. Immunity 2013 2.24
24 Vascular leukocytes contribute to tumor vascularization. Blood 2004 2.03
25 Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007 2.01
26 KLF17 is a negative regulator of epithelial-mesenchymal transition and metastasis in breast cancer. Nat Cell Biol 2009 1.97
27 Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol 2008 1.90
28 CD137 accurately identifies and enriches for naturally occurring tumor-reactive T cells in tumor. Clin Cancer Res 2013 1.90
29 The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 2011 1.82
30 Double-negative feedback loop between reprogramming factor LIN28 and microRNA let-7 regulates aldehyde dehydrogenase 1-positive cancer stem cells. Cancer Res 2010 1.78
31 Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. Cancer Res 2013 1.78
32 A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008 1.77
33 Cancer and inflammation: promise for biologic therapy. J Immunother 2010 1.72
34 Integrative genomic analysis of protein kinase C (PKC) family identifies PKCiota as a biomarker and potential oncogene in ovarian carcinoma. Cancer Res 2006 1.70
35 Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002 1.70
36 In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011 1.62
37 Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer. Cancer Res 2003 1.62
38 Tumor vascular proteins as biomarkers in ovarian cancer. J Clin Oncol 2007 1.55
39 Integrative genomic analysis of phosphatidylinositol 3'-kinase family identifies PIK3R3 as a potential therapeutic target in epithelial ovarian cancer. Clin Cancer Res 2007 1.48
40 Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003 1.40
41 Identification of microRNAs regulating reprogramming factor LIN28 in embryonic stem cells and cancer cells. J Biol Chem 2010 1.38
42 Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013 1.37
43 Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth. Cancer Res 2005 1.37
44 Cancer cell lines as genetic models of their parent histology: analyses based on array comparative genomic hybridization. Cancer Res 2007 1.36
45 Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Mol Ther 2011 1.35
46 Intraepithelial T cells and tumor proliferation: impact on the benefit from surgical cytoreduction in advanced serous ovarian cancer. Cancer 2009 1.32
47 HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005 1.28
48 Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response. Cancer Res 2014 1.28
49 Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005 1.25
50 Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci (Landmark Ed) 2009 1.23
51 MicroRNA epigenetic alterations in human cancer: one step forward in diagnosis and treatment. Int J Cancer 2008 1.21
52 Whole tumor antigen vaccines. Semin Immunol 2010 1.19
53 Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome. Genes Chromosomes Cancer 2011 1.18
54 Immunotherapy opportunities in ovarian cancer. Expert Rev Anticancer Ther 2008 1.18
55 Immunotherapy for ovarian cancer: what's next? J Clin Oncol 2010 1.17
56 Predicting time to ovarian carcinoma recurrence using protein markers. J Clin Invest 2013 1.17
57 Involvement of endothelial CD44 during in vivo angiogenesis. Am J Pathol 2006 1.14
58 Identifying alemtuzumab as an anti-myeloid cell antiangiogenic therapy for the treatment of ovarian cancer. J Transl Med 2009 1.10
59 Different effects of glucose starvation on expression and stability of VEGF mRNA isoforms in murine ovarian cancer cells. Biochem Biophys Res Commun 2002 1.10
60 Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. J Transl Med 2011 1.10
61 A combined array-based comparative genomic hybridization and functional library screening approach identifies mir-30d as an oncomir in cancer. Cancer Res 2011 1.10
62 Ovarian cancer early detection claims are biased. Clin Cancer Res 2008 1.10
63 Therapeutic microRNA strategies in human cancer. AAPS J 2009 1.10
64 Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of CD28- antitumor T cells. Cancer Res 2004 1.09
65 MicroRNAs: a new insight into cancer genome. Cell Cycle 2006 1.08
66 A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med 2012 1.07
67 TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients. Clin Cancer Res 2003 1.07
68 Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev 2011 1.06
69 Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005 1.06
70 Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunol Immunother 2011 1.06
71 Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol 2011 1.05
72 Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer. Biochem Biophys Res Commun 2003 1.05
73 Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res 2009 1.05
74 Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels. PLoS One 2012 1.04
75 Letal, A tumor-associated NKG2D immunoreceptor ligand, induces activation and expansion of effector immune cells. Cancer Biol Ther 2003 1.03
76 Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization. Neoplasia 2012 1.02
77 miRNAs in human cancer. Methods Mol Biol 2012 1.01
78 Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines. Int Rev Immunol 2011 1.01
79 A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013 1.01
80 Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells. J Transl Med 2008 1.00
81 Use of immuno-LCM to identify the in situ expression profile of cellular constituents of the tumor microenvironment. Cancer Biol Ther 2006 1.00
82 A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med 2013 0.99
83 The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade. Gynecol Oncol 2009 0.99
84 The oncogene phosphatidylinositol 3'-kinase catalytic subunit alpha promotes angiogenesis via vascular endothelial growth factor in ovarian carcinoma. Cancer Res 2003 0.99
85 Herpes virus oncolytic therapy reverses tumor immune dysfunction and facilitates tumor antigen presentation. Cancer Biol Ther 2008 0.97
86 Regulatory T cells: a new frontier in cancer immunotherapy. Adv Exp Med Biol 2008 0.97
87 Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses. PLoS One 2011 0.97
88 TIE-2 and VEGFR kinase activities drive immunosuppressive function of TIE-2-expressing monocytes in human breast tumors. Clin Cancer Res 2013 0.97
89 Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation. PLoS One 2009 0.97
90 Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 2010 0.96
91 Tumor endothelial marker 1-specific DNA vaccination targets tumor vasculature. J Clin Invest 2014 0.96
92 Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18. J Transl Med 2009 0.96
93 In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. Mol Imaging Biol 2009 0.96
94 Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy. J Transl Med 2011 0.96
95 A xenograft mouse model coupled with in-depth plasma proteome analysis facilitates identification of novel serum biomarkers for human ovarian cancer. J Proteome Res 2011 0.95
96 Beyond CA125: the coming of age of ovarian cancer biomarkers. Are we there yet? Biomark Med 2009 0.95
97 Integrated analysis of multiple microarray datasets identifies a reproducible survival predictor in ovarian cancer. PLoS One 2011 0.94
98 Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. PLoS One 2008 0.94
99 miRNA genetic alterations in human cancers. Expert Opin Biol Ther 2007 0.94
100 Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform. J Immunol Methods 2010 0.94
101 T-cell and NK-cell infiltration into solid tumors: a key limiting factor for efficacious cancer immunotherapy. Cancer Discov 2014 0.93
102 Interferon beta adenoviral gene therapy in a patient with ovarian cancer. Nat Clin Pract Oncol 2006 0.92
103 Ultraconserved elements: genomics, function and disease. RNA Biol 2008 0.91
104 Novel surface targets and serum biomarkers from the ovarian cancer vasculature. Cancer Biol Ther 2011 0.91
105 Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. J Transl Med 2008 0.90
106 High-throughput biomarker segmentation on ovarian cancer tissue microarrays via hierarchical normalized cuts. IEEE Trans Biomed Eng 2011 0.89
107 Optimizing parameters for clinical-scale production of high IL-12 secreting dendritic cells pulsed with oxidized whole tumor cell lysate. J Transl Med 2011 0.88
108 Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 2003 0.88
109 Transcriptional regulation of PIK3CA oncogene by NF-kappaB in ovarian cancer microenvironment. PLoS One 2008 0.88
110 Varying coefficient model with unknown within-subject covariance for analysis of tumor growth curves. Biometrics 2008 0.88
111 Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids Surf B Biointerfaces 2013 0.88
112 Specific targeting of cancer cells by multifunctional mitoxantrone-conjugated magnetic nanoparticles. J Drug Target 2013 0.88
113 Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation study. Cancer Immunol Res 2013 0.87
114 Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation. Hum Gene Ther 2002 0.86
115 Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv 2013 0.85
116 MicroRNA in human cancer: one step forward in diagnosis and treatment. Adv Exp Med Biol 2008 0.85
117 Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. Cancer Biol Ther 2006 0.84
118 Hierarchical normalized cuts: unsupervised segmentation of vascular biomarkers from ovarian cancer tissue microarrays. Med Image Comput Comput Assist Interv 2009 0.84
119 Role of vascular leukocytes in ovarian cancer neovascularization. Adv Exp Med Biol 2008 0.83
120 Tissue-based immune monitoring II: multiple tumor sites reveal immunologic homogeneity in serous ovarian carcinoma. Cancer Biol Ther 2011 0.82
121 Tumor vascular biomarkers: new opportunities for cancer diagnostics. Cancer Biomark 2011 0.81
122 Know thy enemy: Why are tumor-infiltrating regulatory T cells so deleterious? Oncoimmunology 2012 0.81
123 Immune prognostic factors in ovarian cancer: lessons from translational research. Dis Markers 2007 0.80
124 RNA interference: a potential strategy for isoform-specific phosphatidylinositol 3-kinase targeted therapy in ovarian cancer. Cancer Biol Ther 2004 0.80
125 Inhibitory B7 family members in human ovarian carcinoma. Adv Exp Med Biol 2008 0.79
126 Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opin Biol Ther 2015 0.79
127 TIE2-expressing monocytes: a novel cellular biomarker for hepatocellular carcinoma? Hepatology 2013 0.78
128 A new twist on radiation oncology: low-dose irradiation elicits immunostimulatory macrophages that unlock barriers to tumor immunotherapy. Cancer Cell 2013 0.78
129 Biological therapy with oncolytic herpesvirus. Adv Exp Med Biol 2008 0.78
130 The fibronectin receptor alpha5 integrin subunit is upregulated by cell-cell adhesion via a cyclic AMP-dependent mechanism: implications for human trophoblast migration. Am J Obstet Gynecol 2005 0.77
131 Tissue-based immune monitoring I: tumor core needle biopsies allow in-depth interrogation of the tumor microenvironment. Cancer Biol Ther 2011 0.77
132 Targeting cytokines: production and characterization of anti-TNF-α scFvs by phage display technology. Curr Pharm Des 2013 0.76
133 Luteogenic hormones act through a vascular endothelial growth factor-dependent mechanism to up-regulate alpha 5 beta 1 and alpha v beta 3 integrins, promoting the migration and survival of human luteinized granulosa cells. Am J Pathol 2007 0.76
134 Conference scene: Immune signatures in the tumor and beyond. Immunotherapy 2012 0.75
135 [Not Available]. Rev Med Suisse 2016 0.75
136 [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"]. Rev Med Suisse 2016 0.75
137 Expression profile of microRNA in epithelial cancer: diagnosis, classification and prediction. Expert Opin Med Diagn 2009 0.75
138 Report on the ISBTC mini-symposium on biologic effects of targeted therapeutics. J Immunother 2007 0.75
139 Interrogating open issues in cancer medicine with patient-derived xenografts. Nat Rev Cancer 2017 0.75
140 Cancer immunotherapy: hype or ripe? [corrected]. Eur J Immunol 2014 0.75